Anti-PD-L1 CAR-NK was combined with anti-PD-1 and IL-15 superagonist, N-803 to boost NK cell ability in killing carcinoma in vivo while reducing T cell exhaustion and mediating T cell responses via IFN-γ release which is induced by IL-15 (107). This evidence concerns the gene IL15 and carcinoma.